A novel approach to brachytherapy in hepatocellular carcinoma using a phosphorous{sup 32} ({sup 32}P) brachytherapy delivery device-a first-in-man study
- Department of Nuclear Medicine, Singapore General Hospital (Singapore)
- Department of General Surgery, Singapore General Hospital (Singapore)
- Department of Radiology, Singapore General Hospital (Singapore)
- Radiology Clinic, Mount Elizabeth Medical Centre (Singapore)
- Clinical Trials Resource Centre, Singapore General Hospital (Singapore)
- Department of Radiation Oncology, National Cancer Centre (Singapore)
- pSiOncology Pte. Ltd. (Singapore)
- pSiMedica Ltd., Malvern (United Kingdom)
- Department of General Surgery and Experimental Surgery, Singapore General Hospital (Singapore)
Purpose: While potentially very useful, percutaneously delivered brachytherapy of inoperable intra-abdominal solid tumors faces significant technical challenges. This first-in-man study is designed to determine the safety profile and therapeutic efficacy of a novel phosphorous ({sup 32}P) brachytherapy device (BrachySil) in patients with unresectable hepatocellular carcinoma. Methods and Materials: Patients received single percutaneous and transperitoneal implantations of BrachySil under local anesthesia directly into liver tumors under ultrasound or computed tomographic guidance, at an activity level of 4 MBq/cc of tumor. Toxicity was assessed by the nature, incidence, and severity of adverse events (Common Toxicity Criteria scores) and by hematology and clinical chemistry parameters. Target tumor response was assessed with computed tomographic scans at 12 and 24 weeks postimplantation using World Health Organization criteria. Results: Implantations were successfully carried out in 8 patients (13-74 MBq, mean 40 MBq per tumor) awake and under local anesthesia. Six of the 8 patients reported 19 adverse events, but no serious events were attributable to the study device. Changes in hematology and clinical chemistry were similarly minimal and reflected progressive underlying hepatic disease. All targeted tumors were responding at 12 weeks, with complete response (100% regression) in three lesions. At the end of the study, there were two complete responses, two partial responses, three stable diseases, and one progressive disease. Conclusion: Percutaneous implantation of this novel {sup 32}P brachytherapy device into hepatocellular carcinoma is safe and well tolerated. A significant degree of antitumor efficacy was demonstrated at this low dose that warrants further investigation.
- OSTI ID:
- 20944730
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 67, Issue 3; Other Information: DOI: 10.1016/j.ijrobp.2006.09.011; PII: S0360-3016(06)02992-0; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Propofol Compared to Midazolam Sedation and to General Anesthesia for Percutaneous Microwave Ablation in Patients with Hepatic Malignancies: A Single-Center Comparative Analysis of Three Historical Cohorts
Inverse Planned High-Dose-Rate Brachytherapy for Locoregionally Advanced Cervical Cancer: 4-Year Outcomes